Despite significant delays related to COVID-19, in late 2022 BioKier completed a 12-week clinical study (Study Number CL-501) conducted at three investigational sites: Duke University, Kannapolis NC; Duke University, Pickett Road, NC; and Pennington Biomedical Research, Baton Rouge, LA.
ClinicalTrials.gov Identifier: NCT04279444